The study also included researchers from University of Pecs in Hungary
Similarly, the sirtuin 1 activator, SRT2104, demonstrated to mimic the beneficial effects of exercise and enhance muscle function and regeneration, and mitochondrial function, thereby promoting recovery in Duchenne muscular dystrophy models [69]
Damage to the cauda equina nerves can lead to cauda equina syndrome
Months 1-2 (Initial Titration): Maintain weights from before starting medication Focus on consistent training despite side effects Priority is showing up, not pushing intensity If you miss workouts due to nausea, dont compensate by training harder Months 3-6 (Adaptation Phase): Attempt modest strength increases (2.5-5 pounds on upper body, 5-10 pounds on lower body every 3-4 weeks) If strength stalls, thats acceptable maintenance is success Increase reps before increasing weight (if you can do 12 reps with good form, add weight) Months 7-11 (Maintenance Phase): Continue training at maintained strength levels Accept that weight loss velocity is slowing Focus shifts to body composition refinement Consider adding 1 additional set per exercise if recovery permits MY UNCONVENTIONAL RECOMMENDATION I actually tell patients to stop tracking their one-rep maxes during Retatrutide treatment
Comparative Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists With Regard to 6-Month Glycaemic Control and Weight Outcomes in Patients With Type 2 Diabetes
Endogenously, GLP-1 is secreted by intestinal L cells in response to food, and has multiple roles: enhancing insulin secretion (in a glucose-dependent way), reducing glucagon secretion, slowing gastric emptying, increasing feelings of fullness/satiety, and improving glucose disposal in peripheral tissues
